Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Stemline Therapeutics Inc. STML

Healthcare Biotechnology
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an... see more

Recent & Breaking News (NDAQ:STML)

Wall Street Fundamentals Releases New In-Depth Stock Reports on ADHD, BLUE, STML and XLRN

Accesswire December 11, 2013

Stemline Therapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference

Globe Newswire December 5, 2013

Stemline Therapeutics Announces the Presentation of Clinical Trial Results With a Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Society of Neuro-Oncology (SNO) Annual Meeting

Globe Newswire November 22, 2013

Stemline Therapeutics Announces Clinical Trial Results With SL-701, a Phase 2 Therapeutic for High-Grade Glioma, in an Additional Indication: Data to be Presented at the Society of Neuro-Oncology (SNO) Annual Meeting

Globe Newswire November 19, 2013

Stemline Therapeutics Announces Five Presentations at the American Society of Hematology (ASH) Annual Meeting, Including a Clinical Update of SL-401 in BPDCN

Globe Newswire November 14, 2013

Stemline Therapeutics, Inc. and The Leukemia & Lymphoma Society Announce Collaboration to Accelerate the Development of SL-401 in Hematologic Cancers and Increase Awareness of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Globe Newswire October 29, 2013

Stemline Therapeutics Announces Oral Presentation of SL-401, a Clinical-Stage Targeted Therapy, Demonstrating Notable Preclinical Activity in an Additional Indication, Chronic Myeloid Leukemia (CML), at the 15th International Conference on CML

Globe Newswire September 25, 2013

Stemline Therapeutics to Present at the Aegis Capital Corporation 2013 Healthcare Conference

Globe Newswire September 19, 2013

Stemline Therapeutics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference

Globe Newswire September 4, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on CFN, SMI, STML and TDC

Accesswire August 30, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on CGIX, ESPR, OMED and STML

Accesswire August 26, 2013

Five Star Equities Issues New Research Reports on ODP, SGOC, SSH and STML

Accesswire August 22, 2013

Stemline Therapeutics, Inc. to Present at the 2013 Wedbush Life Sciences Conference

Globe Newswire August 7, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on MENT, NFG, RATE and STML

Accesswire July 31, 2013

LifeSci Advisors Initiates Coverage of Stemline Therapeutics

Marketwired July 29, 2013

Five Star Equities Issues New Research Reports on CZR, NIHD, PCYC and STML

Accesswire July 11, 2013

Stemline Therapeutics, Inc. to Present at the JMP Securities Healthcare Conference

Globe Newswire July 3, 2013

Stemline Therapeutics, Inc. Added to Russell 3000(R) Index

Globe Newswire July 1, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AMCC, GEVO, PRXI and STML

Accesswire June 19, 2013

Stemline Therapeutics' SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Globe Newswire June 10, 2013